Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

Leukemia

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Leukemia

Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R

doi: 10.1038/s41375-025-02664-w

Leukemia

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Leukemia

Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Gao S, Rane D, Guo S

doi: 10.1038/s41375-025-02608-4

Leukemia

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial

Haematologica

Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Žak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP

doi: 10.3324/haematol.2024.286623

Leukemia

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY

Leuk Lymphoma

Mauro MJ, Hehlmann R, Williams LA, Goldberg SL, Michallet M, Gambacorti-Passerini C, Tang D, DeGutis IS, McBride A, Parsons L, Montelongo M, Cortes JE

doi: 10.1080/10428194.2025.2495369

Leukemia

Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements

Leukemia

Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E

doi: 10.1038/s41375-025-02634-2

Leukemia

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Am J Hematol

Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM

doi: 10.1002/ajh.27561

Leukemia

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Leuk Lymphoma

Shadman M, Salkar M, Srivastava B, Karve S, Emond B, Gogna P, Manceur AM, Lafeuille MH, Rava A, Sun H, Howarth A, Tomicki S, Agatep B, Jones B, Franceschini E, Saifan C, Bacchus S, Roeker L, Stephens DM

doi: 10.1080/10428194.2024.2402814

Skin Cancer

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study

Eur J Cancer

Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S

doi: 10.1016/j.ejca.2024.115099

Further Publications

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies

Lancet Oncol

Khatsuria F, McMullan C, Aiyegbusi OL, Shaw KL, Iqbal R, Kinsella F, Wilson K, Pyatt L, Lewis M, Wheldon SMR, Burns D, Chakraverty R, Calvert M, Hughes SE

doi: 10.1016/S1470-2045(24)00256-0

Related content

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY

Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies